p300/CBP - Network of Cancer Research

DS17701585 is a Highly Selective, Orally Active EP300 and CBP Inhibitor

DS17701585 (Compound 11) is a highly selective, orally active EP300 and CBP inhibitor with IC50 values of 0.15, 0.040, 0.45 and 0.70 µM against CBP, EP300, H3K27 and SOX2. Besides, DS17701585 has the…

Cancer

L-Moses Disrupts PCAF-Brd Histone H3.3 Interaction

Louis Gilman April 21, 2021

Bromodomains proteins (Brds) bind to acetylated lysines (KAc) through the Brd acetyllysine-binding site. Misregulation of these proteins is linked to the onset and progression of multiple disease states. They include…

DS17701585 is a Highly Selective, Orally Active EP300 and CBP Inhibitor

L-Moses Disrupts PCAF-Brd Histone H3.3 Interaction

You Missed

BI 7446 is a STING Agonist for Immuno-oncology Research

JNJ-38877605 is an Orally Active c-Met Inhibitor for Solid Tumour Research

OATD-02 is an Orally Active Arginase 1/2 Inhibitor for Melanoma Research

INCB086550 is an Orally Active PD-L1 Inhibitor for Multiple Cancers Research